

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application of:	Dasseux <i>et al.</i>	Confirmation No.:	5585
Serial No.:	10/099,836	Art Unit:	1639
Filed:	March 15, 2002	Examiner:	Bennett M. Celsa
For:	APOLIPOPROTEIN A-I AGONISTS AND THEIR USE TO TREAT DYSLIPIDEMIC DISORDERS		
		Attorney Docket No.:	9196-0022-999 (PC20700H)

RECEIVED
CENTRAL FAX CENTER
MAR 21 2006

REPLY AND AMENDMENT AFTER FINAL REJECTION (37 C.F.R. § 1.116)

Mail Stop AF
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

The enclosed Reply and Amendment under 37 C.F.R. § 1.116 is in reply to the Office Action dated July 8, 2005, for the above-identified patent application. Applicants respectfully request that the Examiner enter the present amendment after final rejection, which will resolve all outstanding rejections and place the application in condition for allowance. Pursuant to 37 CFR 1.116(2), Applicants are canceling certain claims and complying with a requirement of form by submitting Terminal Disclaimers in response to Obviousness-Type Double Patenting rejections, set forth in the previous Office Action.

Amendments to the Claims shown in the listing of claims begin on page 2.

Remarks begin on page 8.

Also enclosed are:

a Petition for Extension of Time from November 8, 2005, to and including January 8, 2006, for responding to the Office Action;

Terminal Disclaimers;

a Revocation of Power of Attorney with New Power of Attorney and Change of Correspondence Address Form; and

a Notice of Appeal.